PRESS RELEASE
Lund, December 14 2020

With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01

In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies, not least the important biodistribution and toxicology studies, with the aim of starting studies in humans, so-called clinical studies, in 2022. A central area for both the final preclinical studies and future clinical studies is the GMP manufacturing of CG01. CombiGene has therefore recruited Martin Linhult, as the company's CMC expert (Chemistry, Manufacturing and Controls) starting in December, 2020. In addition to his expertise in the CMC field, CombiGene will benefit greatly from his experience in taking pharmaceutical products all the way to market.

Martin Linhult holds a PhD in molecular biology at Royal Institute of Technology (KTH) in Stockholm (1998-2003) and holds a Master of Chemical Engineering from the same university. In addition, Martin has extensive experience from a number of senior positions in the Swedish pharmaceutical industry and is used to interacting with regulatory authorities at an international level, including the FDA and EMA. Martin has worked in all parts of the production process of biological drugs and was responsible for building up the production unit at Octapharma. Martin will primarily work on the various aspects of the manufacture of the drug candidate CG01, which is now entering a very intensive development phase. Martin will report to CombiGenes Chief Research and Development Officer Karin Agerman.

"I am incredibly pleased that we have succeeded in recruiting Martin Linhult to CombiGene", says Karin Agerman. *"Martin has exactly the deep knowledge in all aspects of the production of biological drugs that we are looking for and has, in addition to this, experience of taking a product all the way to market. His broad international experience in regulatory matters will be of great benefit in the further development of CG01."*

CombiGene is now continuing the process of strengthening the company with one or two more people.

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Tel: +46 (0)704 66 31 63
jan.nilsson@combigene.com

Bert Junno, Chairman of the board
Tel: +46(0) 70 777 22 09
bert.junno@combigene.com

Please read INGENEIOUS, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. INGENEIOUS and press releases are available at www.combigene.com